

1 AN ACT relating to licensees of the Kentucky Board of Medical Licensure.

2 ***Be it enacted by the General Assembly of the Commonwealth of Kentucky:***

3 ➔Section 1. KRS 311.842 is amended to read as follows:

4 (1) The board shall promulgate administrative regulations in accordance with KRS  
5 Chapter 13A relating to the licensing and regulation *of physician assistants,*  
6 including *but not limited to:*

7 *(a) Temporary licensing of physician assistants;*

8 *(b) Professional standards for prescribing and administering controlled*  
9 *substances; and*

10 *(c) Professional standards for prescribing or administering Buprenorphine-*  
11 *Mono-Product or Buprenorphine-Combined-with-Naloxone.*

12 (2) The board shall establish a nine (9) member Physician Assistant Advisory  
13 Committee that shall review and make recommendations to the board regarding all  
14 matters relating to physician assistants that come before the board, including but not  
15 limited to:

16 (a) Applications for physician assistant licensing;

17 (b) Licensing renewal requirements;

18 (c) Approval of supervising physicians;

19 (d) Disciplinary actions; and

20 (e) Promulgation and revision of administrative regulations.

21 (3) Members of the Physician Assistant Advisory Committee shall be appointed by the  
22 board for four (4) year terms and shall consist of:

23 (a) Five (5) practicing physician assistants;

24 (b) Two (2) supervising physicians;

25 (c) One (1) member of the board; and

26 (d) One (1) citizen at large.

27 (4) The chairperson of the committee shall be elected by a majority vote of the

1 committee members and shall be responsible for presiding over meetings that shall  
2 be held on a regular basis.

3 (5) Members shall receive reimbursement for expenditures relating to attendance at  
4 committee meetings consistent with state policies for reimbursement of travel  
5 expenses for state employees.

6 (6) Nothing in this chapter shall be construed to require licensing of a physician  
7 assistant student enrolled in a physician assistant or surgeon assistant program  
8 accredited by the Accreditation Review Commission on Education for Physician  
9 Assistants or its successor agencies or of a physician assistant employed in the  
10 service of the federal government while performing duties relating to that  
11 employment.

12 ➔Section 2. KRS 311.844 is amended to read as follows:

13 (1) To be licensed by the board as a physician assistant, an applicant shall:

14 (a) Submit a completed application form with the required fee;

15 (b) Be of good character and reputation;

16 (c) Be a graduate of an approved program; and

17 (d) Have passed an examination approved by the board within three (3) attempts.

18 (2) A physician assistant who is authorized to practice in another state and who is in  
19 good standing may apply for licensure by endorsement from the state of his or her  
20 credentialing if that state has standards substantially equivalent to those of this  
21 Commonwealth.

22 (3) A physician assistant's license shall be **valid for two (2) years and shall be** renewed  
23 **by the board** upon fulfillment of the following requirements:

24 (a) The holder shall be of good character and reputation;

25 (b) The holder shall provide evidence of completion, during the previous two (2)  
26 years, of a minimum of one hundred (100) hours of continuing education  
27 approved by the American Medical Association, the American Osteopathic

1 Association, the American Academy of Family Physicians, the American  
2 Academy of Physician Assistants, or by another entity approved by the board.  
3 The one hundred (100) hours of continuing education required by this  
4 paragraph shall include:

5 1. During the first two (2) years of licensure or prior to the first licensure  
6 renewal:[::]

7 a. One (1) continuing education course on the human  
8 immunodeficiency virus and acquired immunodeficiency  
9 syndrome; and

10 b. One and one-half (1.5) hours of continuing education in the  
11 prevention and recognition of pediatric abusive head trauma, as  
12 defined in KRS 620.020; and

13 2. If the license holder is authorized, pursuant to subsection (5) of  
14 Section 5 of this Act, to prescribe and administer Schedule III, IV, or  
15 V controlled substances, a minimum of five (5) hours of approved  
16 continuing education relating to controlled substance diversion, pain  
17 management, addiction disorders, use of the electronic system for  
18 monitoring controlled substances established in KRS 218A.202, or any  
19 combination of two (2) or more of these subjects;

20 (c) The holder, if authorized, pursuant to subsection (5) of Section 5 of this Act,  
21 to prescribe and administer Schedule III, IV, or V controlled substances,  
22 shall provide evidence of completion, during the previous two (2) years, of a  
23 minimum of five (5) hours, in addition to the continuing education  
24 requirements established in paragraph (b) of this subsection, of continuing  
25 education relating to controlled substance diversion, pain management,  
26 addiction disorders, use of the electronic system for monitoring controlled  
27 substances established in KRS 218A.202, or any combination of two (2) or

1            ~~*more of these subjects*~~ [ The holder shall provide evidence of completion of a  
 2            continuing education course on the human immunodeficiency virus and  
 3            acquired immunodeficiency syndrome;

4            ~~(d)~~ As a part of the continuing education requirements that the board adopts to  
 5            ensure continuing competency of present and future licensees the board shall  
 6            ensure that physician's assistants shall demonstrate completion of a one-time  
 7            training course of one and one half (1.5) hours of training covering the  
 8            prevention and recognition of pediatric abusive head trauma, as defined in  
 9            KRS 620.020. The one and one half (1.5) hours of continuing education  
 10           required under this section shall be included in the current number of required  
 11           continuing education hours]; and

12           ~~(d)~~~~(e)~~ The holder shall provide proof of current certification with the National  
 13           Commission on Certification of Physician Assistants.

14           ➔ Section 3. KRS 311.850 is amended to read as follows:

15           (1) The board may revoke, suspend, deny, decline to renew, limit, or restrict the license  
 16           of a physician assistant, or may fine, reprimand or place a physician assistant on  
 17           probation for no more than five (5) years upon proof that a physician assistant has:

18           (a) Knowingly made or presented or caused to be made or presented any false,  
 19           fraudulent, or forged statement, writing, certificate, diploma, or other  
 20           document relating to an application for licensure;

21           (b) Practiced, aided, or abetted in the practice of fraud, forgery, deception,  
 22           collusion, or conspiracy relating to an examination for licensure;

23           (c) Been convicted of a crime as defined in KRS 335B.010, if in accordance with  
 24           KRS Chapter 335B;

25           (d) *Been convicted of a misdemeanor offense under KRS Chapter 510 involving*  
 26           *a patient or a felony offense under KRS Chapter 510, KRS 530.064, or*  
 27           *531.310, or has been found by the board to have had sexual contact, as*

- 1           *defined in KRS 510.010, with a patient while the patient was under the care*  
2           *of the physician assistant or the physician assistant's supervising physician;*  
3           (e) Become addicted to *a controlled substance, as defined in KRS*  
4           *311.550(26)*~~or is an abuser of alcohol, drugs, or any illegal substance];~~  
5           (f) *Become a chronic or persistent alcoholic, as defined in KRS 311.550(25);*  
6           (g)~~(e)~~ *Been unable or is unable to practice medicine according to acceptable*  
7           *and prevailing standards of care by reason of mental or physical illness or*  
8           *other condition including but not limited to physical deterioration that*  
9           *adversely affects cognitive, motor, or perceptive skills, or by reason of an*  
10           *extended absence from the active practice of medicine*~~Developed a physical~~  
11           ~~or mental disability or other condition that presents a danger in continuing to~~  
12           ~~practice medicine to patients, the public, or other health care personnel];~~  
13           (h)~~(f)~~ Knowingly made or caused to be made or aided or abetted in the making  
14           of a false statement in any document executed in connection with the practice  
15           of medicine or osteopathy;  
16           (i)~~(g)~~ Performed any act or service as a physician assistant without a  
17           designated supervising physician;  
18           (j)~~(h)~~ Exceeded the scope of medical services described by the supervising  
19           physician in the applications required under KRS 311.854;  
20           (k)~~(i)~~ Exceeded the scope of practice for which the physician assistant was  
21           credentialed by the governing board of a hospital or licensed health care  
22           facility under KRS 311.856 and 311.858;  
23           (l)~~(j)~~ Aided, assisted, or abetted the unlawful practice of medicine or  
24           osteopathy or any healing art, including the unlawful practice of physician  
25           assistants;  
26           (m)~~(k)~~ Willfully violated a confidential communication;  
27           (n)~~(l)~~ Performed the services of a physician assistant in an unprofessional,

1 incompetent, or grossly or chronically negligent manner;

2 ~~(o)~~~~(m)~~ Been removed, suspended, expelled, or placed on probation by any  
3 health care facility or professional society for unprofessional conduct,  
4 incompetence, negligence, or violation of any provision of this section or KRS  
5 311.858 or 311.862;

6 ~~(p)~~~~(n)~~ Violated any applicable provision of administrative regulations relating  
7 to physician assistant practice;

8 ~~(q)~~~~(o)~~ Violated any term of probation or other discipline imposed by the  
9 board;~~(r)~~

10 ~~(r)~~~~(p)~~ Failed to complete the required number of hours of approved continuing  
11 education; **or**

12 ~~(s)~~ **Engaged in dishonorable, unethical, or unprofessional conduct of character**  
13 **likely to deceive, defraud, or harm the public or any member thereof, as**  
14 **described in KRS 311.597.**

15 (2) All disciplinary proceedings against a physician assistant shall be conducted in  
16 accordance with the provisions of KRS 311.591, 311.592, 311.593, 311.599, and  
17 KRS Chapter 13B and related administrative regulations promulgated under KRS  
18 Chapter 311.

19 ➔Section 4. KRS 311.856 is amended to read as follows:

20 A supervising physician shall:

21 (1) Restrict the services of a physician assistant to services within the physician  
22 assistant's scope of practice and to the provisions of KRS 311.840 to 311.862;

23 (2) **Prohibit a physician assistant from dispensing controlled substances;**

24 ~~(3)~~ Prohibit a physician assistant from prescribing or ~~administering~~~~[dispensing]~~  
25 controlled substances, **except as provided in subsection (5) of Section 5 of this Act;**

26 ~~(4)~~~~(3)~~ Inform all patients in contact with a physician assistant of the status of the  
27 physician assistant;

- 1 ~~(5)~~~~(4)~~ Post a notice stating that a physician assistant practices medicine or  
2 osteopathy in all locations where the physician assistant may practice;
- 3 ~~(6)~~~~(5)~~ Require a physician assistant to wear identification that clearly states that he  
4 or she is a physician assistant;
- 5 ~~(7)~~~~(6)~~ Prohibit a physician assistant from independently billing any patient or other  
6 payor for services rendered by the physician assistant;
- 7 ~~(8)~~~~(7)~~ If necessary, participate with the governing body of any hospital or other  
8 licensed health care facility in a credentialing process established by the facility;
- 9 ~~(9)~~~~(8)~~ Not require a physician assistant to perform services or other acts that the  
10 physician assistant feels incapable of carrying out safely and properly;
- 11 ~~(10)~~~~(9)~~ Maintain adequate, active, and continuous supervision of a physician  
12 assistant's activities to assure that the physician assistant is performing as directed  
13 and complying with the requirements of KRS 311.840 to 311.862 and all related  
14 administrative regulations;
- 15 ~~(11)~~~~(10)~~ Review and countersign a sufficient number of overall medical notes written  
16 by the physician assistant to ensure quality of care provided by the physician  
17 assistant and outline the specific parameters for review of countersignatures in the  
18 application required by KRS 311.854. Countersignature requirements shall be  
19 determined by the supervising physician, practice, or institution. As used in this  
20 subsection:
- 21 (a) "Practice" means a medical practice composed of two (2) or more physicians  
22 organized to provide patient care services, regardless of its legal form or  
23 ownership; and
- 24 (b) "Institution" means all or part of any public or private facility, place, building,  
25 or agency, whether organized for profit or not, that is used, operated, or  
26 designed to provide medical diagnosis, treatment, nursing, rehabilitative, or  
27 preventive care;

1 ~~(12)~~~~(11)~~ (a) Reevaluate the reliability, accountability, and professional knowledge of  
 2 a physician assistant two (2) years after the physician assistant's original  
 3 licensure in this Commonwealth and every two (2) years thereafter; and

4 (b) Based on the reevaluation, recommend approval or disapproval of licensure or  
 5 renewal to the board; and

6 ~~(13)~~~~(12)~~ Notify the board within three (3) business days if the supervising physician:

7 (a) Ceases to supervise or employ the physician assistant; or

8 (b) Believes in good faith that a physician assistant violated any disciplinary rule  
 9 of KRS 311.840 to 311.862 or related administrative regulations.

10 ➔Section 5. KRS 311.858 is amended to read as follows:

11 (1) A physician assistant may perform medical services and procedures within the  
 12 scope of medical services and procedures described in the initial or any  
 13 supplemental application received by the board under KRS 311.854.

14 (2) A physician assistant shall be considered an agent of the supervising physician in  
 15 performing medical services and procedures described in the initial application or  
 16 any supplemental application received by the board under KRS 311.854.

17 (3) A physician assistant may initiate evaluation and treatment in emergency situations  
 18 without specific approval.

19 (4) A physician assistant may prescribe and administer all nonscheduled legend drugs  
 20 and medical devices to the extent~~as~~ delegated by the supervising physician. A  
 21 physician assistant who is delegated prescribing authority may request, receive, sign  
 22 for, and distribute professional samples of nonscheduled legend~~sample~~ drugs to  
 23 patients.

24 (5) (a) A physician assistant who has been approved by the board pursuant to  
 25 paragraph (b) of this subsection, may prescribe and administer Schedules  
 26 III, IV, and V controlled substances, as described in KRS Chapter 218A, to  
 27 the extent delegated by the supervising physician and as permitted under



1 paragraphs (c), (d), and (e) of this subsection.

2 (b) Before a physician assistant engages in prescribing or administering  
3 controlled substances, the physician assistant shall:

4 1. Have at least one (1) year of experience as a licensed and practicing  
5 physician assistant;

6 2. Submit to the board a completed application for prescriptive authority  
7 for controlled substances signed by the physician assistant's  
8 supervising physician in accordance with Section 4 of this Act;

9 3. Receive from the board, or its executive director, a notice that the  
10 application for prescriptive authority has been approved; and

11 4. Obtain a Controlled Substance Registration Certificate through the  
12 United States Drug Enforcement Administration and register with the  
13 electronic system for monitoring controlled substances established in  
14 KRS 218A.202 and any other applicable state controlled substance  
15 regulatory authority.

16 (c) Prescriptions issued by a physician assistant for Schedule III controlled  
17 substances, as described in KRS 218A.060 and 218A.080, shall be limited to  
18 a thirty (30) day supply without any refill.

19 (d) Prescriptions issued by a physician assistant for Schedule IV or V  
20 controlled substances, as described in KRS 218A.100 and 218A.120, shall  
21 be limited to the original prescription and refills not to exceed a six (6)  
22 month supply.

23 (e) Notwithstanding paragraph (d) of this subsection, prescriptions issued by a  
24 physician assistant for benzodiazepines or Carisoprodol shall be limited to a  
25 thirty (30) day supply without any refill.

26 (6) A physician assistant shall not submit direct billing for medical services and  
27 procedures performed by the physician assistant.

1 ~~(7)~~~~(6)~~ A physician assistant may perform local infiltrative anesthesia under the  
2 provisions of subsection (1) of this section, but a physician assistant shall not  
3 administer or monitor general or regional anesthesia unless the requirements of  
4 KRS 311.862 are met.

5 ~~(8)~~~~(7)~~ A physician assistant may perform services in the offices or clinics of the  
6 supervising physician. A physician assistant may also render services in hospitals or  
7 other licensed health care facilities only with written permission of the facility's  
8 governing body, and the facility may restrict the physician assistant's scope of  
9 practice within the facility as deemed appropriate by the facility.

10 ~~(9)~~~~(8)~~ A physician assistant shall not practice medicine or osteopathy independently.  
11 Each physician assistant shall practice under supervision as defined in KRS  
12 311.840.

13 ➔SECTION 6. A NEW SECTION OF KRS 311.840 TO 311.862 IS CREATED  
14 TO READ AS FOLLOWS:

15 *(1) When a hearing or inquiry panel, as described in KRS 311.591, has probable*  
16 *cause to believe a physician assistant is suffering from a physical or mental*  
17 *condition that might impede his or her ability to practice competently, the panel*  
18 *upon consideration of recommendations of the Physician Assistant Advisory*  
19 *Committee established in KRS 311.842, may order the physician assistant to*  
20 *undergo a physical or mental examination by person designated by the panel.*

21 *(2) Failure of a physician assistant to submit to such an examination when directed,*  
22 *unless the failure is due to circumstances beyond his or her control, shall*  
23 *constitute an admission that the concerned physician assistant has developed*  
24 *such a physical or mental disability, or other condition, that continued practice is*  
25 *dangerous to patients or to the public; said failure shall constitute a default and a*  
26 *final order may be entered without the taking of testimony or presentation of*  
27 *evidence.*

1 **(3) A physician assistant whose license has been suspended, limited, restricted, or**  
 2 **revoked under this section and Section 3 of this Act, shall at reasonable intervals**  
 3 **be afforded an opportunity to demonstrate that he or she can resume the**  
 4 **competent practice of medicine with reasonable skill and safety to patients.**

5 ➔Section 7. KRS 311.616 is amended to read as follows:

6 (1) The board may establish by contract, **including with a nonprofit corporation,** or  
 7 otherwise **the Kentucky Physician Health Foundation**~~[an impaired physicians~~  
 8 ~~program]~~ to promote the early identification, intervention, treatment, and  
 9 rehabilitation of **individuals licensed by the board**~~[physicians]~~ who may be  
 10 impaired by reason of illness, alcohol or drug abuse, or as a result of any physical or  
 11 mental condition.

12 (2) The board may promulgate administrative regulations under the provisions of KRS  
 13 Chapter 13A to implement any program formed under this section and may expend  
 14 any funds necessary to provide for operational expenses of a program formed under  
 15 this section.

16 ➔Section 8. KRS 311.619 is amended to read as follows:

17 (1) All information, interviews, reports, statements, memoranda, or other documents  
 18 furnished to or produced by the program formed under KRS 311.616, as well as all  
 19 communications to or from the program, and any findings, conclusions,  
 20 interventions, treatment, or rehabilitation, or other proceedings of the program  
 21 which in any way pertain or refer to **an individual licensed by the board**~~[a~~  
 22 ~~physician]~~ who may be, or who is actually, impaired shall be privileged and  
 23 confidential.

24 (2) All records and proceedings of the program which pertain or refer to **an individual**  
 25 **licensed by the board**~~[a physician]~~ who may be, or who actually is, impaired shall  
 26 be privileged and confidential and shall be used by the program and its members  
 27 only in the exercise of the proper function of the program and shall not be

1 considered public records nor shall they be subject to court subpoena or subject to  
 2 discovery or introduction as evidence in any civil, criminal, or administrative  
 3 proceedings except as described in subsection (3) of this section.

- 4 (3) The program may disclose information relative to an impaired **individual licensed**  
 5 **by the board**~~[physician]~~ only:
- 6 (a) When it is essential to disclose such information to further the intervention,  
 7 treatment, or rehabilitation needs of the impaired **individual**~~[physician]~~, and  
 8 then only to those persons or organizations with a need to know;
- 9 (b) When its release is authorized in writing by the impaired  
 10 **individual**~~[physician]~~; or
- 11 (c) When the program is required to make a report to the board.

12 (4) The program shall report any suspected violation of KRS 311.595 to the board.

13 ➔Section 9. KRS 218A.010 is amended to read as follows:

14 As used in this chapter:

- 15 (1) "Administer" means the direct application of a controlled substance, whether by  
 16 injection, inhalation, ingestion, or any other means, to the body of a patient or  
 17 research subject by:
- 18 (a) A practitioner or by his or her authorized agent under his or her immediate  
 19 supervision and pursuant to his or her order; or
- 20 (b) The patient or research subject at the direction and in the presence of the  
 21 practitioner;
- 22 (2) "Anabolic steroid" means any drug or hormonal substance chemically and  
 23 pharmacologically related to testosterone that promotes muscle growth and includes  
 24 those substances classified as Schedule III controlled substances pursuant to KRS  
 25 218A.020 but does not include estrogens, progestins, and anticosteroids;
- 26 (3) "Cabinet" means the Cabinet for Health and Family Services;
- 27 (4) "Carfentanil" means any substance containing any quantity of carfentanil, or any of

1 its salts, isomers, or salts of isomers;

2 (5) "Certified community based palliative care program" means a palliative care  
3 program which has received certification from the Joint Commission;

4 (6) "Child" means any person under the age of majority as specified in KRS 2.015;

5 (7) "Cocaine" means a substance containing any quantity of cocaine, its salts, optical  
6 and geometric isomers, and salts of isomers;

7 (8) "Controlled substance" means methamphetamine, or a drug, substance, or  
8 immediate precursor in Schedules I through V and includes a controlled substance  
9 analogue;

10 (9) (a) "Controlled substance analogue," except as provided in paragraph (b) of this  
11 subsection, means a substance:

12 1. The chemical structure of which is substantially similar to the structure  
13 of a controlled substance in Schedule I or II; and

14 2. Which has a stimulant, depressant, or hallucinogenic effect on the  
15 central nervous system that is substantially similar to or greater than the  
16 stimulant, depressant, or hallucinogenic effect on the central nervous  
17 system of a controlled substance in Schedule I or II; or

18 3. With respect to a particular person, which such person represents or  
19 intends to have a stimulant, depressant, or hallucinogenic effect on the  
20 central nervous system that is substantially similar to or greater than the  
21 stimulant, depressant, or hallucinogenic effect on the central nervous  
22 system of a controlled substance in Schedule I or II.

23 (b) Such term does not include:

24 1. Any substance for which there is an approved new drug application;

25 2. With respect to a particular person, any substance if an exemption is in  
26 effect for investigational use for that person pursuant to federal law to  
27 the extent conduct with respect to such substance is pursuant to such

1 exemption; or

2 3. Any substance to the extent not intended for human consumption before  
3 the exemption described in subparagraph 2. of this paragraph takes  
4 effect with respect to that substance;

5 (10) "Counterfeit substance" means a controlled substance which, or the container or  
6 labeling of which, without authorization, bears the trademark, trade name, or other  
7 identifying mark, imprint, number, or device, or any likeness thereof, of a  
8 manufacturer, distributor, or dispenser other than the person who in fact  
9 manufactured, distributed, or dispensed the substance;

10 (11) "Dispense" means to deliver a controlled substance to an ultimate user or research  
11 subject by or pursuant to the lawful order of a practitioner, including the packaging,  
12 labeling, or compounding necessary to prepare the substance for that delivery;

13 (12) "Dispenser" means a person who lawfully dispenses a Schedule II, III, IV, or V  
14 controlled substance to or for the use of an ultimate user;

15 (13) "Distribute" means to deliver other than by administering or dispensing a controlled  
16 substance;

17 (14) "Dosage unit" means a single pill, capsule, ampule, liquid, or other form of  
18 administration available as a single unit;

19 (15) "Drug" means:

20 (a) Substances recognized as drugs in the official United States Pharmacopoeia,  
21 official Homeopathic Pharmacopoeia of the United States, or official National  
22 Formulary, or any supplement to any of them;

23 (b) Substances intended for use in the diagnosis, care, mitigation, treatment, or  
24 prevention of disease in man or animals;

25 (c) Substances (other than food) intended to affect the structure or any function of  
26 the body of man or animals; and

27 (d) Substances intended for use as a component of any article specified in this

1 subsection.

2 It does not include devices or their components, parts, or accessories;

3 (16) "Fentanyl" means a substance containing any quantity of fentanyl, or any of its salts,  
4 isomers, or salts of isomers;

5 (17) "Fentanyl derivative" means a substance containing any quantity of any chemical  
6 compound, except compounds specifically scheduled as controlled substances by  
7 statute or by administrative regulation pursuant to this chapter, which is structurally  
8 derived from 1-ethyl-4-(N-phenylamido) piperadine:

9 (a) By substitution:

- 10 1. At the 2-position of the 1-ethyl group with a phenyl, furan, thiophene, or  
11 ethyloxotetrazole ring system; and  
12 2. Of the terminal amido hydrogen atom with an alkyl, alkoxy, cycloalkyl,  
13 or furanyl group; and

14 (b) Which may be further modified in one (1) or more of the following ways:

- 15 1. By substitution on the N-phenyl ring to any extent with alkyl, alkoxy,  
16 haloalkyl, hydroxyl, or halide substituents;  
17 2. By substitution on the piperadine ring to any extent with alkyl, allyl,  
18 alkoxy, hydroxy, or halide substituents at the 2-, 3-, 5-, and/or 6-  
19 positions;  
20 3. By substitution on the piperadine ring to any extent with a phenyl,  
21 alkoxy, or carboxylate ester substituent at the 4- position; or  
22 4. By substitution on the 1-ethyl group to any extent with alkyl, alkoxy, or  
23 hydroxy substituents;

24 (18) "Good faith prior examination," as used in KRS Chapter 218A and for criminal  
25 prosecution only, means an in-person medical examination of the patient conducted  
26 by the prescribing practitioner or other health-care professional routinely relied  
27 upon in the ordinary course of his or her practice, at which time the patient is

- 1 physically examined and a medical history of the patient is obtained. "In-person"  
2 includes telehealth examinations. This subsection shall not be applicable to hospice  
3 providers licensed pursuant to KRS Chapter 216B;
- 4 (19) "Hazardous chemical substance" includes any chemical substance used or intended  
5 for use in the illegal manufacture of a controlled substance as defined in this section  
6 or the illegal manufacture of methamphetamine as defined in KRS 218A.1431,  
7 which:
- 8 (a) Poses an explosion hazard;  
9 (b) Poses a fire hazard; or  
10 (c) Is poisonous or injurious if handled, swallowed, or inhaled;
- 11 (20) "Heroin" means a substance containing any quantity of heroin, or any of its salts,  
12 isomers, or salts of isomers;
- 13 (21) "Hydrocodone combination product" means a drug with:
- 14 (a) Not more than three hundred (300) milligrams of dihydrocodeinone, or any of  
15 its salts, per one hundred (100) milliliters or not more than fifteen (15)  
16 milligrams per dosage unit, with a fourfold or greater quantity of an  
17 isoquinoline alkaloid of opium; or  
18 (b) Not more than three hundred (300) milligrams of dihydrocodeinone, or any of  
19 its salts, per one hundred (100) milliliters or not more than fifteen (15)  
20 milligrams per dosage unit, with one (1) or more active, nonnarcotic  
21 ingredients in recognized therapeutic amounts;
- 22 (22) "Immediate precursor" means a substance which is the principal compound  
23 commonly used or produced primarily for use, and which is an immediate chemical  
24 intermediary used or likely to be used in the manufacture of a controlled substance  
25 or methamphetamine, the control of which is necessary to prevent, curtail, or limit  
26 manufacture;
- 27 (23) "Industrial hemp" has the same meaning as in KRS 260.850;



- 1 (24) "Industrial hemp products" has the same meaning as in KRS 260.850;
- 2 (25) "Intent to manufacture" means any evidence which demonstrates a person's  
3 conscious objective to manufacture a controlled substance or methamphetamine.  
4 Such evidence includes but is not limited to statements and a chemical substance's  
5 usage, quantity, manner of storage, or proximity to other chemical substances or  
6 equipment used to manufacture a controlled substance or methamphetamine;
- 7 (26) "Isomer" means the optical isomer, except the Cabinet for Health and Family  
8 Services may include the optical, positional, or geometric isomer to classify any  
9 substance pursuant to KRS 218A.020;
- 10 (27) "Manufacture," except as provided in KRS 218A.1431, means the production,  
11 preparation, propagation, compounding, conversion, or processing of a controlled  
12 substance, either directly or indirectly by extraction from substances of natural  
13 origin or independently by means of chemical synthesis, or by a combination of  
14 extraction and chemical synthesis, and includes any packaging or repackaging of the  
15 substance or labeling or relabeling of its container except that this term does not  
16 include activities:
- 17 (a) By a practitioner as an incident to his or her administering or dispensing of a  
18 controlled substance in the course of his or her professional practice;
- 19 (b) By a practitioner, or by his or her authorized agent under his supervision, for  
20 the purpose of, or as an incident to, research, teaching, or chemical analysis  
21 and not for sale; or
- 22 (c) By a pharmacist as an incident to his or her dispensing of a controlled  
23 substance in the course of his or her professional practice;
- 24 (28) "Marijuana" means all parts of the plant *Cannabis* sp., whether growing or not; the  
25 seeds thereof; the resin extracted from any part of the plant; and every compound,  
26 manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin  
27 or any compound, mixture, or preparation which contains any quantity of these

- 1 substances. The term "marijuana" does not include:
- 2 (a) Industrial hemp that is in the possession, custody, or control of a person who  
3 holds a license issued by the Department of Agriculture permitting that person  
4 to cultivate, handle, or process industrial hemp;
- 5 (b) Industrial hemp products that do not include any living plants, viable seeds,  
6 leaf materials, or floral materials;
- 7 (c) The substance cannabidiol, when transferred, dispensed, or administered  
8 pursuant to the written order of a physician practicing at a hospital or  
9 associated clinic affiliated with a Kentucky public university having a college  
10 or school of medicine;
- 11 (d) For persons participating in a clinical trial or in an expanded access program,  
12 a drug or substance approved for the use of those participants by the United  
13 States Food and Drug Administration;
- 14 (e) A cannabidiol product derived from industrial hemp, as defined in KRS  
15 260.850; or
- 16 (f) A cannabidiol product approved as a prescription medication by the United  
17 States Food and Drug Administration;
- 18 (29) "Medical history," as used in KRS Chapter 218A and for criminal prosecution only,  
19 means an accounting of a patient's medical background, including but not limited to  
20 prior medical conditions, prescriptions, and family background;
- 21 (30) "Medical order," as used in KRS Chapter 218A and for criminal prosecution only,  
22 means a lawful order of a specifically identified practitioner for a specifically  
23 identified patient for the patient's health-care needs. "Medical order" may or may  
24 not include a prescription drug order;
- 25 (31) "Medical record," as used in KRS Chapter 218A and for criminal prosecution only,  
26 means a record, other than for financial or billing purposes, relating to a patient,  
27 kept by a practitioner as a result of the practitioner-patient relationship;

- 1 (32) "Methamphetamine" means any substance that contains any quantity of  
2 methamphetamine, or any of its salts, isomers, or salts of isomers;
- 3 (33) "Narcotic drug" means any of the following, whether produced directly or indirectly  
4 by extraction from substances of vegetable origin, or independently by means of  
5 chemical synthesis, or by a combination of extraction and chemical synthesis:
- 6 (a) Opium and opiate, and any salt, compound, derivative, or preparation of  
7 opium or opiate;
- 8 (b) Any salt, compound, isomer, derivative, or preparation thereof which is  
9 chemically equivalent or identical with any of the substances referred to in  
10 paragraph (a) of this subsection, but not including the isoquinoline alkaloids  
11 of opium;
- 12 (c) Opium poppy and poppy straw;
- 13 (d) Coca leaves, except coca leaves and extracts of coca leaves from which  
14 cocaine, ecgonine, and derivatives of ecgonine or their salts have been  
15 removed;
- 16 (e) Cocaine, its salts, optical and geometric isomers, and salts of isomers;
- 17 (f) Ecgonine, its derivatives, their salts, isomers, and salts of isomers; and
- 18 (g) Any compound, mixture, or preparation which contains any quantity of any of  
19 the substances referred to in paragraphs (a) to (f) of this subsection;
- 20 (34) "Opiate" means any substance having an addiction-forming or addiction-sustaining  
21 liability similar to morphine or being capable of conversion into a drug having  
22 addiction-forming or addiction-sustaining liability. It does not include, unless  
23 specifically designated as controlled under KRS 218A.020, the dextrorotatory  
24 isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does  
25 include its racemic and levorotatory forms;
- 26 (35) "Opium poppy" means the plant of the species *papaver somniferum* L., except its  
27 seeds;

- 1 (36) "Person" means individual, corporation, government or governmental subdivision  
2 or agency, business trust, estate, trust, partnership or association, or any other legal  
3 entity;
- 4 (37) "Physical injury" has the same meaning it has in KRS 500.080;
- 5 (38) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing;
- 6 (39) "Pharmacist" means a natural person licensed by this state to engage in the practice  
7 of the profession of pharmacy;
- 8 (40) "Practitioner" means a physician, dentist, podiatrist, veterinarian, scientific  
9 investigator, optometrist as authorized in KRS 320.240, advanced practice  
10 registered nurse as authorized under KRS 314.011, physician assistant as  
11 authorized under Section 5 of this Act, or other person licensed, registered, or  
12 otherwise permitted by state or federal law to acquire, distribute, dispense, conduct  
13 research with respect to, or to administer a controlled substance in the course of  
14 professional practice or research in this state. "Practitioner" also includes a  
15 physician, dentist, podiatrist, veterinarian, or advanced practice registered nurse  
16 authorized under KRS 314.011 who is a resident of and actively practicing in a state  
17 other than Kentucky and who is licensed and has prescriptive authority for  
18 controlled substances under the professional licensing laws of another state, unless  
19 the person's Kentucky license has been revoked, suspended, restricted, or probated,  
20 in which case the terms of the Kentucky license shall prevail;
- 21 (41) "Practitioner-patient relationship," as used in KRS Chapter 218A and for criminal  
22 prosecution only, means a medical relationship that exists between a patient and a  
23 practitioner or the practitioner's designee, after the practitioner or his or her  
24 designee has conducted at least one (1) good faith prior examination;
- 25 (42) "Prescription" means a written, electronic, or oral order for a drug or medicine, or  
26 combination or mixture of drugs or medicines, or proprietary preparation, signed or  
27 given or authorized by a medical, dental, chiropody, veterinarian, optometric

- 1 practitioner, or advanced practice registered nurse, and intended for use in the  
2 diagnosis, cure, mitigation, treatment, or prevention of disease in man or other  
3 animals;
- 4 (43) "Prescription blank," with reference to a controlled substance, means a document  
5 that meets the requirements of KRS 218A.204 and 217.216;
- 6 (44) "Presumptive probation" means a sentence of probation not to exceed the maximum  
7 term specified for the offense, subject to conditions otherwise authorized by law,  
8 that is presumed to be the appropriate sentence for certain offenses designated in  
9 this chapter, notwithstanding contrary provisions of KRS Chapter 533. That  
10 presumption shall only be overcome by a finding on the record by the sentencing  
11 court of substantial and compelling reasons why the defendant cannot be safely and  
12 effectively supervised in the community, is not amenable to community-based  
13 treatment, or poses a significant risk to public safety;
- 14 (45) "Production" includes the manufacture, planting, cultivation, growing, or harvesting  
15 of a controlled substance;
- 16 (46) "Recovery program" means an evidence-based, nonclinical service that assists  
17 individuals and families working toward sustained recovery from substance use and  
18 other criminal risk factors. This can be done through an array of support programs  
19 and services that are delivered through residential and nonresidential means;
- 20 (47) "Salvia" means *Salvia divinorum* or Salvinorin A and includes all parts of the plant  
21 presently classified botanically as *Salvia divinorum*, whether growing or not, the  
22 seeds thereof, any extract from any part of that plant, and every compound,  
23 manufacture, derivative, mixture, or preparation of that plant, its seeds, or its  
24 extracts, including salts, isomers, and salts of isomers whenever the existence of  
25 such salts, isomers, and salts of isomers is possible within the specific chemical  
26 designation of that plant, its seeds, or extracts. The term shall not include any other  
27 species in the genus *salvia*;

- 1 (48) "Second or subsequent offense" means that for the purposes of this chapter an  
2 offense is considered as a second or subsequent offense, if, prior to his or her  
3 conviction of the offense, the offender has at any time been convicted under this  
4 chapter, or under any statute of the United States, or of any state relating to  
5 substances classified as controlled substances or counterfeit substances, except that  
6 a prior conviction for a nontrafficking offense shall be treated as a prior offense  
7 only when the subsequent offense is a nontrafficking offense. For the purposes of  
8 this section, a conviction voided under KRS 218A.275 or 218A.276 shall not  
9 constitute a conviction under this chapter;
- 10 (49) "Sell" means to dispose of a controlled substance to another person for  
11 consideration or in furtherance of commercial distribution;
- 12 (50) "Serious physical injury" has the same meaning it has in KRS 500.080;
- 13 (51) "Synthetic cannabinoids or piperazines" means any chemical compound which is  
14 not approved by the United States Food and Drug Administration or, if approved,  
15 which is not dispensed or possessed in accordance with state and federal law, that  
16 contains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1-  
17 Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-  
18 naphthoyl)indole; 1-Pentyl-3-(1-naphthoyl)indole; dexanabinol (HU-211); or any  
19 compound in the following structural classes:
- 20 (a) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole  
21 structure with substitution at the nitrogen atom of the indole ring by an alkyl,  
22 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
23 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further  
24 substituted in the indole ring to any extent and whether or not substituted in  
25 the naphthyl ring to any extent. Examples of this structural class include but  
26 are not limited to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081,  
27 JWH-122, JWH-200, and AM-2201;

- 1 (b) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole  
2 structure with substitution at the nitrogen atom of the indole ring by an alkyl,  
3 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
4 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further  
5 substituted in the indole ring to any extent and whether or not substituted in  
6 the phenyl ring to any extent. Examples of this structural class include but are  
7 not limited to JWH-167, JWH-250, JWH-251, and RCS-8;
- 8 (c) Benzoylindoles: Any compound containing a 3-(benzoyl)indole structure with  
9 substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,  
10 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,  
11 or 2-(4-morpholinyl)ethyl group whether or not further substituted in the  
12 indole ring to any extent and whether or not substituted in the phenyl ring to  
13 any extent. Examples of this structural class include but are not limited to  
14 AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;
- 15 (d) Cyclohexylphenols: Any compound containing a 2-(3-  
16 hydroxycyclohexyl)phenol structure with substitution at the 5-position of the  
17 phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
18 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl  
19 group whether or not substituted in the cyclohexyl ring to any extent.  
20 Examples of this structural class include but are not limited to CP 47,497 and  
21 its C8 homologue (cannabicyclohexanol);
- 22 (e) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-  
23 naphthyl)methane structure with substitution at the nitrogen atom of the indole  
24 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-  
25 methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not  
26 further substituted in the indole ring to any extent and whether or not  
27 substituted in the naphthyl ring to any extent. Examples of this structural class

- 1 include but are not limited to JWH-175, JWH-184, and JWH-185;
- 2 (f) Naphthoypyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole  
3 structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl,  
4 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
5 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further  
6 substituted in the pyrrole ring to any extent and whether or not substituted in  
7 the naphthyl ring to any extent. Examples of this structural class include but  
8 are not limited to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
- 9 (g) Naphthylmethylindenes: Any compound containing a 1-(1-  
10 naphthylmethyl)indene structure with substitution at the 3-position of the  
11 indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
12 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether  
13 or not further substituted in the indene ring to any extent and whether or not  
14 substituted in the naphthyl ring to any extent. Examples of this structural class  
15 include but are not limited to JWH-176;
- 16 (h) Tetramethylcyclopropanoylindoles: Any compound containing a 3-(1-  
17 tetramethylcyclopropoyl)indole structure with substitution at the nitrogen  
18 atom of the indole ring by an alkyl, haloalkyl, cycloalkylmethyl,  
19 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl  
20 group, whether or not further substituted in the indole ring to any extent and  
21 whether or not further substituted in the tetramethylcyclopropyl ring to any  
22 extent. Examples of this structural class include but are not limited to UR-144  
23 and XLR-11;
- 24 (i) Adamantoylindoles: Any compound containing a 3-(1-adamantoyl)indole  
25 structure with substitution at the nitrogen atom of the indole ring by an alkyl,  
26 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
27 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further



1 substituted in the indole ring to any extent and whether or not substituted in  
2 the adamantyl ring system to any extent. Examples of this structural class  
3 include but are not limited to AB-001 and AM-1248; or

4 (j) Any other synthetic cannabinoid or piperazine which is not approved by the  
5 United States Food and Drug Administration or, if approved, which is not  
6 dispensed or possessed in accordance with state and federal law;

7 (52) "Synthetic cathinones" means any chemical compound which is not approved by the  
8 United States Food and Drug Administration or, if approved, which is not dispensed  
9 or possessed in accordance with state and federal law (not including bupropion or  
10 compounds listed under a different schedule) structurally derived from 2-  
11 aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or  
12 thiophene ring systems, whether or not the compound is further modified in one (1)  
13 or more of the following ways:

14 (a) By substitution in the ring system to any extent with alkyl, alkylendioxy,  
15 alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further  
16 substituted in the ring system by one (1) or more other univalent substituents.  
17 Examples of this class include but are not limited to 3,4-  
18 Methylenedioxcathinone (bk-MDA);

19 (b) By substitution at the 3-position with an acyclic alkyl substituent. Examples of  
20 this class include but are not limited to 2-methylamino-1-phenylbutan-1-one  
21 (buphedrone);

22 (c) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or  
23 methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a  
24 cyclic structure. Examples of this class include but are not limited to  
25 Dimethylcathinone, Ethcathinone, and  $\alpha$ -Pyrrolidinopropiophenone ( $\alpha$ -PPP);  
26 or

27 (d) Any other synthetic cathinone which is not approved by the United States

1 Food and Drug Administration or, if approved, is not dispensed or possessed  
2 in accordance with state or federal law;

3 (53) "Synthetic drugs" means any synthetic cannabinoids or piperazines or any synthetic  
4 cathinones;

5 (54) "Telehealth" has the same meaning it has in KRS 311.550;

6 (55) "Tetrahydrocannabinols" means synthetic equivalents of the substances contained in  
7 the plant, or in the resinous extractives of the plant Cannabis, sp. or synthetic  
8 substances, derivatives, and their isomers with similar chemical structure and  
9 pharmacological activity such as the following:

10 (a) Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers;

11 (b) Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; and

12 (c) Delta 3, 4 cis or trans tetrahydrocannabinol, and its optical isomers;

13 (56) "Traffic," except as provided in KRS 218A.1431, means to manufacture, distribute,  
14 dispense, sell, transfer, or possess with intent to manufacture, distribute, dispense,  
15 or sell a controlled substance;

16 (57) "Transfer" means to dispose of a controlled substance to another person without  
17 consideration and not in furtherance of commercial distribution; and

18 (58) "Ultimate user" means a person who lawfully possesses a controlled substance for  
19 his or her own use or for the use of a member of his or her household or for  
20 administering to an animal owned by him or her or by a member of his or her  
21 household.

22 ➔Section 10. The following KRS section is repealed:

23 311.617 Creation, support, and maintenance of committee -- Authority for  
24 administrative regulations.